PT-141 10 mg

Melanocortin Receptor Agonist (Research Grade)

In plain terms: This compound acts on receptors in the brain rather than the

bloodstream, distinguishing it from research compounds that work through vascular

pathways. It’s used to isolate central nervous system signaling tied to motivation- and arousal-related behavior, separate from blood-flow mechanisms.

Compound classification PT-141 (bremelanotide) is a synthetic cyclic heptapeptide

studied as a melanocortin receptor agonist with activity at MC3R and MC4R.

Studied mechanism Research has examined PT-141 binding at MC3R/MC4R receptors

concentrated in the hypothalamus and limbic system, and associated downstream cAMP

signaling — a central mechanism distinct from peripherally-acting compounds.

Research findings Preclinical models have examined melanocortin receptor activation

in relation to arousal-related and motivational-behavior parameters, supporting its use

as a research tool for isolating CNS-driven signaling independent of peripheral

pathways.

Effects reported in research literature:

Nausea

Flushing

Headache

Research status: Research-grade material sold here is not a pharmaceutical product, is

not equivalent to any approved drug formulation, and has not been evaluated for human

safety or efficacy.

Research Use Only: This compound is intended for laboratory research use only. It is

not a drug, dietary supplement, or consumer product, and is not for human or animal

consumption. Statements have not been evaluated by the FDA and are not intended to

diagnose, treat, cure, or prevent any disease.